Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03956355 · ClinicalTrials.gov registry record · Phase 3
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
A Phase 3 study, sponsored by Organon and.
- Completed
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT03956355 is a Phase 3 study that has completed, run by Organon and. The registered enrollment target is 510 participants.
The verdict
NCT03956355, a Phase 3 study, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
Interventions
- DRUG Tapinarof
- DRUG Vehicle Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2020-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03956355
The ClinicalTrials.gov registry entry for NCT03956355 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tapinarof is the first listed.
NCT03956355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03956355 about?
NCT03956355 is a clinical study titled "Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)". This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinaro...
What is the current status of trial NCT03956355?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2019-05-21. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT03956355?
The interventions under investigation include: Tapinarof (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT03956355?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.